TME PHARMA N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1586 EUR | +0.51% |
|
-5.03% | -31.04% |
| 06-27 | TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board | CI |
| 06-19 | TME Pharma: in the red, a broker cuts its target | CF |
TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Calendar
23/10/2024
- Q2 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.04% | 7M | |
| +21.85% | 46.93B | |
| +37.63% | 39.08B | |
| -8.05% | 38.48B | |
| +29.04% | 31.01B | |
| -13.75% | 26.14B | |
| +10.65% | 25.88B | |
| +38.43% | 12.53B | |
| -6.92% | 11.36B | |
| -12.29% | 10.65B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- Biotech Group TMA Pharma's CFO to Leave by 2022-end
